Stine JG, Caldwell SH

Language: English
References: 10
Page: 460-462
PDF size: 116.42 Kb.

Text Extraction

In this issue of Annals of Hepatology, Castiella, et al. examined the relationship between liver iron concentration (LIC), hyperferritinemia and metabolic syndrome in a Spanish cohort of patients.
Metabolic syndrome is defined by the presence of at least three of the following: obesity (increased waistline circumference), atherogenic dyslipidemia (hypertriglyceridemia and/or low high-density lipoprotein), hypertension or insulin resistance (elevated glucose levels or frank diabetes).

REFERENCES

1. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2: 231-7.

2. Alkerwi A, Donneau AF, Sauvageot N, Lair ML, Scheen A, Albert A, Guillaume M.Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study. BMC Public Health 2011; 11: 4.

3. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-90.

4. Chen LY, Chang SD, Sreenivasan GM, Tsang PW, Broady RC, Li CH, Zypchen LN.Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann Hematol 2011; 90: 139-43.

5. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (10 Suppl. 3): S158-68.

6. Liu WX, Zhang XL, Gao X, Yang L, Li BX, Liu DW. Association between HLA-DQ gene polymorphisms and different These findings are novel and shed more light on the pathophysiology of AIH as IL-17F is known to interact with both TNFα and IL-6, and may accelerate hepatic fibrosis. Taken as a whole, the available literature seems to be unclear as to the exact implications of particular cytokine profiles, however, this study suggests that future investigation into the complex interaction between IL-17F, TNFα and IL-6 would be of interest. It is our hope that this may offer a more upstream therapeutic target in those patients with refractory disease rather than the more downstream, less specific agents currently available including mycophenolate, tacrolimus and even TNFα antagonists. outcomes of hepatitis B virus infection. Zhonghua Liu Xing Bing Xue Za Zhi 2016; 37: 384-8.

7. Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, Kobayashi T, et al. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res 2014; 44: E447-E454.

8. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.

9. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. Journal of Pediatric Gastroenterology and Nutrition. 1995; 20: 23-7.

10. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C.Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.